Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
limosilactobacillus fermentum ABF21069
- Development stage
- Preclinical
- Lead developer
- AceBiome
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Limosilactobacillus fermentum ABF21069 is a research-stage probiotic bacterial strain investigated for its potential therapeutic effects on obesity and metabolic dysfunction-associated fatty liver disease (MAFLD). As a live biotherapeutic, it functions by modulating the gut microbiota and host metabolism. Preclinical evidence suggests that ABF21069 produces exopolysaccharides and downregulates intestinal sugar transport genes, thereby reducing sugar absorption. Furthermore, it has been shown to enhance lipid metabolism by increasing the expression of genes involved in β-oxidation, thermogenesis, and lipolysis, while simultaneously reducing hepatic inflammation and fat accumulation. In mouse models, it demonstrated synergistic efficacy when administered in combination with Lactobacillus gasseri BNR17, leading to significant reductions in body weight and serum leptin levels.
- Other names
- Limosilactobacillus fermentum ABF21069L. fermentum ABF21069
Beyond the preview
Go deeper on limosilactobacillus fermentum ABF21069.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on limosilactobacillus fermentum ABF21069.